BTIG Downgrades Apogee Therapeutics to Neutral
BTIG analyst Julian Harrison downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga